BioStack has launched a data infrastructure network spanning more than 100 million de-identified patient records across the United States, India, Brazil, and Argentina. The San Francisco-based company also announced a US$9.5 million Seed round led by Peak XV and Y Combinator, with participation from several other investors. The platform connects fragmented clinical information to give AI and biotech companies high-quality data for training models on disease progression, treatments, and patient outcomes.
Addressing the Fragmented Patient Data Problem
Patient histories and other clinical data are often scattered across hospitals, providers, and technology systems, leaving clinicians without a complete view of a patient's treatment. BioStack creates workflows that bring together notes, labs, imaging, medications, treatments, and outcomes from disparate health systems and geographies. By connecting these elements, the company provides a more comprehensive patient view and supports hospital-level and population-level discovery.
Longitudinal Data for Research and AI Development
Beyond clinical workflows, BioStack creates proprietary datasets from de-identified data collected from each provider system. These datasets support medical research, drug development, and the training and evaluation of healthcare AI models. By linking biological and clinical data with treatment histories and long-term outcomes, the company helps researchers understand how different interventions affected patient health over time.
Creating a Feedback Loop Between Care and Innovation
BioStack also builds a feedback loop between clinical care and medical innovation. As more longitudinal patient information becomes available, researchers and AI developers can gain a richer understanding of disease progression and treatment response. Healthcare providers, in turn, can benefit from these new insights and more personalized approaches to care.
Global Reach and Specialized Data Assets
BioStack works with hospitals across the United States, Brazil, India, and Argentina, giving it access to a diverse patient population and healthcare environments. In India, the company is helping connect cancer patients with an investigational cancer vaccine program, supporting biotech development and offering eligible patients access to personalized treatments. It has also combined several hundred thousand fragmented X-rays, MRIs, and CT scans with pathology and clinical records to support AI agents that evaluate treatment options and likely outcomes.
Platform Applications and Research Potential
BioStack's platform supports medical AI model development and evaluation, clinical research, disease modeling, biomarker discovery, patient stratification, and treatment response analysis. These capabilities make the company's proprietary datasets valuable to biotech firms advancing drug development and precision medicine. The approach also connects clinical care with research in ways that could accelerate more personalized therapies.
Investor Confidence and Expansion Plans
The US$9.5 million Seed round will support BioStack's expansion in the United States and international markets, technology platform development, and engineering and research team growth. Pushpak Kedia, Vice President at Peak XV, said the next frontier of healthcare AI will depend on better models and access to high-quality, longitudinal data reflecting how patients are treated over time. He added that BioStack is building critical infrastructure with the potential to become a key data layer for medical AI.
BioStack's launch marks an important step toward a more connected and useful foundation for healthcare AI and biomedical research. By transforming fragmented patient records into longitudinal, de-identified datasets, the company aims to support clinicians, researchers, and AI developers working on the next generation of medicine. With new funding and a growing international footprint, BioStack is positioned to help shape how medical AI models are trained, evaluated, and applied in real-world care.